» Articles » PMID: 34273014

Radiotherapy Role in Non-seminomatous Germ Cell Tumors, Radiobiological and Technical Issues of an Unexplored Scenario

Overview
Specialty Oncology
Date 2021 Jul 17
PMID 34273014
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Historically, non-seminomatous germ cell tumor (NSGCT) has been considered a radio-resistant disease, excluding radiotherapy (RT) from curative strategies. However, case series exploring the use of radiation treatment in this setting are often outdated, and prospective ongoing studies testing new radiotherapeutic approaches in NSGCT are lacking. Considering that tremendous advances in radiotherapy technology have enabled improved precision in RT delivery as well as dose escalation while decreasing treatment-related morbidity, we overviewed the currently available literature to explore the radiobiological basis, the technical issues, and potential strategies for implementation of RT in the management of this clinical entity. The purpose of the present overview is to provide insight for future research in this unexplored scenario. In summary, the biological rationale for RT use and potential implementation with systemic therapies exist, especially considering the advantage of new technologies, which were unavailable in the era of early literature reports. The NSGCT radioresistance paradigm could be based only on the fact that effective treatment schedules were simply undeliverable with older RT techniques due to toxicity issues, but the availability of actual techniques may prompt further exploration to offer treatment alternatives to these patients. Ongoing trials on this issue are lacking, but potential areas of research are platinum-refractory disease and consolidation therapy for residual masses after PST.

Citing Articles

Spinal Metastases in Non-Seminomatous Germ Cell Testicular Tumors: Prognosis and Integrated Therapeutic Approaches-A Systematic Review with an Institutional Case Illustration.

Scalia G, Ferini G, Shams Z, Graziano F, Ponzo G, Giurato E Curr Oncol. 2024; 31(12):7459-7475.

PMID: 39727674 PMC: 11674372. DOI: 10.3390/curroncol31120551.


Competing risk nomogram predicting cause-specific mortality in older patients with testicular germ cell tumors.

Wu X, Zhou M, Lyu J, Chen L Front Med (Lausanne). 2024; 11:1327485.

PMID: 38695022 PMC: 11061386. DOI: 10.3389/fmed.2024.1327485.


A Comprehensive Review of Current Trends in the Diagnosis and Treatment of Ovarian Germ Cell Tumors.

Dantkale K, Agrawal M Cureus. 2024; 16(1):e52650.

PMID: 38380211 PMC: 10877227. DOI: 10.7759/cureus.52650.

References
1.
Stephenson A, Bosl G, Bajorin D, Stasi J, Motzer R, Sheinfeld J . Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion. J Urol. 2005; 174(2):557-60. DOI: 10.1097/01.ju.0000165163.03805.37. View

2.
Stephenson A, Klein E . Surgical management of low-stage nonseminomatous germ cell testicular cancer. BJU Int. 2009; 104(9 Pt B):1362-8. DOI: 10.1111/j.1464-410X.2009.08860.x. View

3.
McCaffrey J, Mazumdar M, Bajorin D, Bosl G, Vlamis V, Motzer R . Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J Clin Oncol. 1997; 15(7):2559-63. DOI: 10.1200/JCO.1997.15.7.2559. View

4.
Loehrer Sr P, GONIN R, Nichols C, Weathers T, Einhorn L . Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol. 1998; 16(7):2500-4. DOI: 10.1200/JCO.1998.16.7.2500. View

5.
Bhatia S, Abonour R, Porcu P, Seshadri R, Nichols C, Cornetta K . High-dose chemotherapy as initial salvage chemotherapy in patients with relapsed testicular cancer. J Clin Oncol. 2000; 18(19):3346-51. DOI: 10.1200/JCO.2000.18.19.3346. View